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Abstract
Background Antipsychotic use is associated with serious
adverse events in the elderly, and consequently can lead to
further healthcare utilization such as nursing home
admission.
Objective To evaluate the risk of nursing home admission
associated with typical versus atypical antipsychotic use
among the US community-dwelling elderly population.
Methods A retrospective cohort design was conducted
using Medicare and Medicaid Analytical eXtract (MAX)
data from four US states. The cohort included all dual-
eligible beneficiaries (aged C65 years) who initiated an-
tipsychotic treatment during July 2001–December 2003.
The risk of nursing home admission during the 6-month
follow-up period was evaluated using Cox proportional
hazards regression model and extended Cox model strati-
fied on matched pairs based on propensity score, using
atypical agents as the reference category.
Results The average risk of nursing home admission was
similar among atypical antipsychotic users compared to
typical users (hazard ratio [HR] 0.91; 95 % confidence
interval [CI] 0.81–1.01]) However, the results of extended
Cox regression revealed that the effect varied with time;
typical users had a moderately lower risk of nursing home
admission within the initial 90 days of therapy [HR 0.87;
95 % CI 0.77–0.97] but substantial risk was observed for
90–180 days of typical antipsychotic exposure [HR 1.58;
95 % CI 1.08–2.12].
Conclusion The study found that, among elderly benefi-
ciaries, typical antipsychotic use was associated with a
time-dependent increase in risk of nursing home admission.
Given the safety concerns with atypical antipsychotics and
their extensive use in the elderly, there is a need to be
cautious while prescribing antipsychotics in the vulnerable
elderly population.
Key Points
Antipsychotics, mainly atypical agents, are
frequently prescribed in the elderly for the treatment
and management of psychoses and behavioral
problems in dementia. Use of antipsychotics is
associated with adverse events, and consequently can
lead to nursing home admission in this population.
The current study evaluated the risk of nursing home
admission associated with typical versus atypical
antipsychotic use among the dual-eligible elderly in
the US.
The findings suggest that typical antipsychotic use is
associated with a time-dependent increase in risk of
nursing home admission. Given the safety concerns
with atypical antipsychotics and their extensive use
in the elderly, there is a need to be cautious while
prescribing antipsychotics in the vulnerable elderly
population.
Introduction
Antipsychotics are frequently prescribed in the elderly for
the treatment and management of psychoses and behavioral
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problems in dementia [1, 2]. Introduced in the early 1950s,
typical antipsychotics such as haloperidol and thioridazine
were effective in the treatment of schizophrenia. However,
use of these agents was associated with central adverse
events like extrapyramidal symptoms, tardive dyskinesia,
and sedation [1]. Consequently, atypical antipsychotics
such as olanzapine and risperidone were introduced in the
1990s as safer alternatives to typical agents [1–4]. In the
past two decades, use of atypical antipsychotics in the
elderly has considerably increased, from 15 % of total
antipsychotic use in 1996–1998 to 73 % in 2002–2004 [5].
In light of extensive atypical antipsychotic use, results
of large clinical trials suggest that the two classes of
antipsychotics have comparable effectiveness profiles [6, 7].
These findings question the preference of atypical agents
over typical agents. Despite high use, atypical agents are
frequently used for off-label indications like depression,
obsessive compulsive disorder (OCD), post-traumatic
stress disorder (PTSD), and agitation in dementia, among
others, with little evidence base [8]. In addition, use of
atypical agents has been linked to serious adverse events
like cardiometabolic dysfunction, falls/fractures, and
cerebrovascular and other cardiovascular events [9–14]. A
review of 17 placebo-controlled trials by the US Food Drug
and Administration (FDA) revealed a 60–70 % higher risk
of mortality with atypical antipsychotics compared to the
placebo group [15]. This prompted the FDA to issue a
boxed warning on atypical antipsychotics in 2005. Later,
based on evidence of increased mortality risk with the use
of typical agents, the FDA placed a similar black box
warning on typical antipsychotics in 2008 [16]. Overall, the
limited evidence base of antipsychotic use together with
the differential safety profiles of typical and atypical agents
may lead to severe healthcare consequences such as insti-
tutionalization of the elderly. Therefore, there is a need to
examine the comparative healthcare consequences of the
two antipsychotic classes in the elderly population.
Admission to nursing homes constitutes a potential
negative outcome in the elderly due to transitioning of
patients from independent to dependent care. In 2007, the
estimated cost of nursing home care in the US was $150
billion [17]. In addition to high healthcare expenditure,
nursing home admission has been associated with other
adverse consequences like poor quality of care, early
mortality for residents, and emotional and psychological
distress for caregivers. Studies evaluating nursing home
admission among the elderly have identified cognitive
impairment, functional decline, and clinical co-morbidi-
ties as the major risk factors in diverse healthcare set-
tings [18]. Use of medications can be a potentially
modifiable factor that could lead to serious adverse
events, and consequently nursing home admission in the
elderly.
A study by Zuckerman et al. [19] found that inappro-
priate medication use was associated with a 31 % higher
risk of nursing home admission in a cohort of elderly
Medicare beneficiaries. The study further revealed that
inappropriate antipsychotic use had a 2.5-fold higher risk
of nursing home admission, whereas other antipsychotic
use had more than 4 times increased risk compared to non-
use. Another study by Lopez et al. [20] found that in
patients with probable Alzheimer’s disease, there was no
differential risk of the two antipsychotic classes in the
long-term risk of nursing home admission [20]. However,
no study has conducted a head-to-head comparison of the
two antipsychotic classes in terms of nursing home
admission among the elderly, and none focused on the
vulnerable dual-eligible elderly population. Dual-eligible
beneficiaries (those enrolled in both Medicare and Medi-
caid) are poorer and less healthy than the general elderly
population [21–23]. As a result, they have higher unmet
care needs than their non-dual-eligible counterparts [24].
Therefore, the current study sought to examine the risk of




The study used 2001–2003 Medicaid and Medicare data
from Texas, New York, California, and Florida to achieve
the study objective. The above states were chosen to pro-
vide large sample sizes and a representative population of
the US. The years 2001–2003 were selected to allow for
comparable samples for both the drug classes. The Medi-
caid Analytic Extract (MAX) data consists of four analytic
component files—Personal Summary, Prescription, Inpa-
tient, Long Term Care, and Other Services files [25]. The
current study involved the use of Personal Summary, Pre-
scription, Inpatient, and Long Term Care files. The Per-
sonal Summary file records the demographic
characteristics such as the patient’s age, gender, race/eth-
nicity, and eligibility information, among others. The
Prescription file consists of variables like therapeutic class
of the medications prescribed, their National Drug Codes
(NDCs), quantity of service, and days of supply. The
Inpatient file captures data elements like admission date,
beginning date of service, end date of service, and diag-
nostic codes for each admission. The Long Term Care file
includes information on services provided in long-term
care facilities for the Medicaid enrollees. The records in
this file are usually weekly or monthly claims. The types of
services that apply to this file include mental hospital ser-
vices for the elderly, nursing facility services, intermediate
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care services for the mentally retarded, and inpatient psy-
chiatric facilities for individuals aged below 21 years.
The Medicare data consists of beneficiary summary files,
denominator files, and Medicare Provider Analysis and
Review files (MedPAR) [26]. The Beneficiary Summary file
is created annually, and contains demographic and entitle-
ment data for its beneficiaries who were (a) a part of the
CMS Chronic Condition Data Warehouse (CCW) 5 %
sample; (b) documented as being alive for some part of the
calendar year accounted for in the Beneficiary Summary
file; and (c) enrolled in a Medicare program and entitled to
its benefits during the calendar year. The Center of Medi-
care and Medicaid Services (CMS) denominator file con-
tains enrollment information for all the beneficiaries
enrolled in Medicare in a given year. The MedPAR file
contains data on inpatient hospital and skilled nursing
facility (SNF) utilization of the Medicare beneficiaries. All
the Medicare files are linked through a unique identifier.
The Medicaid and Medicare files are also linked through a
unique patient identifier. Additional information on the data
sources can be found elsewhere [27].
Study Sample and Design
The study population included the Medicare and Medicaid-
eligible enrollees, aged 65 years and older, who initiated
treatment with a typical or atypical antipsychotic medica-
tion anytime from 1 July 2001–31 December 2003. A pa-
tient was defined as a dual-eligible beneficiary whose first
prescription of antipsychotic did not include his or her stay
in long-term care or a nursing home facility. Inclusion of
the beneficiaries in the cohort required that they were
continuously eligible for at least 6 months before their first
antipsychotic prescription fill date. Only new users of an-
tipsychotic agents were included in the study to protect
against selection bias among prevalent users from early
symptom emergence, drug intolerance, or treatment fail-
ures [28].
Exposure and Outcome Definitions
Exposure to typical or atypical antipsychotics formed the
primary independent variable of our study. The typical
antipsychotic cohort comprised users of any of the fol-
lowing agents: loxapine, fluphenazine, triflupromazine,
chlorprothixene, haloperidol, chlorpromazine, thioridazine,
promazine, trifluperazine, thiothexene, molindone, per-
phenazine, acetophenazine, mesoridazine, pimozide, and
perphenazine-amitriptyline. The atypical antipsychotic
cohort consisted of users of clozapine, olanzapine, olan-
zapine-fluoxetine, risperidone, quetiapine, ziprasidone, or
aripiprazole. Use of typical and atypical antipsychotic
agents was identified using the corresponding NDCs.
The primary outcome of our study was the time to
nursing home admission among the elderly beneficiaries
during the 6-month follow-up period. Nursing home
admission was defined based on qualified SNF stay using
MedPAR files from Medicare, and Long Term Care files
from Medicaid. The duration of follow-up was based on
previous studies by the authors [29]. Patients were fol-
lowed till the occurrence of nursing home admission or end
of the study period, whichever occurred earlier. Patients
were censored if the study period ended without occurrence
of the event (180 days), or the treatment was discontinued,
the gap between two successive refills of the same class of
medications exceeded 30 days, or the patients switched to a
different class of antipsychotic, died or were lost to follow-
up. The study allowed switching of antipsychotic agents
within the same class. If a patient had only one claim of a
particular antipsychotic agent at the index date, he was
considered in the cohort throughout the length of supply of
that medication. The entire study duration was from 1 July
2001–31 December 2003.
Propensity Score Matching
The propensity score is defined as a subject’s probability to
receive a particular treatment conditional on his observed
covariates [30]. Since antipsychotic treatment was not
randomly assigned to the study population, the two treat-
ment groups differed in various observable and unobserved
characteristics. The use of a propensity score aimed to
achieve a balance in the observed or known confounders
across the typical and atypical users, and thus made the two
groups comparable for analysis. Therefore, a propensity
score-matched retrospective cohort design was used to
examine the association between antipsychotic use and risk
of nursing home admission in the above population.
A large number of covariates were included in the
calculation of propensity score based on previously pub-
lished literature, expert opinions, and evidence of their
association with the outcome [31]. Those variables were
measured for the antipsychotic users based on their health
care utilization 6 months before their first antipsychotic
fill date and included pretreatment characteristics such as
sociodemographics (age, gender, race), clinical charac-
teristics (co-morbidities and co-medications), and severity
of illness. Severity of illness was measured as all-cause
hospitalization in the previous 6-months of index
antipsychotic prescription [32]. Nursing home stay during
the 6 months of index prescription date was also included
as one of the pre-treatment characteristics among the
antipsychotic users.
A logistic regression model was developed using all the
above baseline characteristics to obtain propensity scores
(likelihood ratio [LR]\0.0001; c statistics 0.71). Using the
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resulting propensity scores, patients taking typical
antipsychotics were matched with patients taking atypical
antipsychotics by GREEDY 5 ? 1 matching technique. In
this technique, at each phase of the matching process, a
‘‘greedy’’ approach is used, whereby a control subject is
matched to a treated subject even if it better serves as a
match for another treated subject [33]. This technique
reduces matched-pair bias caused by incomplete and
inexact matching [34]. In the present study, the subjects
treated with typical agents were first matched to the sub-
jects treated with atypical agents on the first five digits of
the propensity score. For those treated subjects who re-
mained unmatched, matching was done based on the first
four digits of the propensity score. This process was re-
peated until the subjects in both the treatment groups were
matched on the first digit of the propensity score. Subjects
in the two treatment groups that remained unmatched were
excluded. If more than one control was found that matched
to a case, the control was selected at random.
Statistical Analysis
The differences in various pretreatment characteristics
between the two groups were evaluated using a chi-square
test for categorical variables and t test for continuous
variables before and after matching. Survival analysis was
then performed on the matched cohort to assess the risk of
nursing home admission between typical versus atypical
antipsychotic users. Kaplan-Meier survival plots were
created to depict the crude (unadjusted) relationships be-
tween typical antipsychotic use versus atypical antipsy-
chotic use and time to nursing home admission. Pairwise
log rank tests were used to compare survival curves for
statistical difference. An a priori value of 0.05 was used to
examine the statistical significance.
Cox proportional-hazards regression model stratified on
matched pairs was used to examine the risk of nursing
home admission between typical users and atypical users,
and the corresponding hazard ratios (HRs) were obtained.
Stratified Cox proportional-hazard model was applied us-
ing the STRATA option of PROC PHREG to account for
matched pair design [33, 34]. Prior to using the Cox
regression model, the Proportional Hazards (PH) assumption
for the model was checked by including the interaction
term between the independent variables and log of time to
nursing home admission. The PH assumption for antipsy-
chotic use was not met at the significance level of 0.05,
indicating that the treatment effect was not constant over
time. In order to adjust for time in our analysis, extended
Cox models were used with heavy side function [35, 36].
Models of nursing home admission within the first 90 days
and from 90–180 days were developed. The cut-off point
of 90 days was selected based on the intersection of the
Kaplan Meier curves of the two drug classes. All analyses
were performed using SAS version 9.2.
Results
Analysis of Medicaid–Medicare dual-eligible data revealed
that between 2001 and 2003 there were 60,131 users of
antipsychotic agents (49,200 atypical and 10,931 typical users)
in the outpatient population of dual-eligible beneficiaries.
The matched cohort had a total of 20,818 patients (10,919
atypical and 10,919 typical users). Table 1 presents the
baseline characteristics of the users of typical and atypical
antipsychotic agents before and after propensity score
matching. It can also be seen from the table that, before
matching, the typical and atypical users differed in a large
number of the pretreatment characteristics. After matching,
nearly all the pretreatment variables were balanced across
the two treatment groups. Figure 1 presents the distribution
of the propensity scores before matching. Figure 2 presents
the distribution of propensity scores after matching. Thus,
propensity score helped achieve a balance in the majority of
the pretreatment characteristics in the two treatment groups.
Overall, there were 2,214 patients who experienced
nursing home admission during the follow-up period.
There were 1,275 events (11.66 %) in the atypical cohort
and 939 (8.59 %) events in the typical cohort. Figure 3
presents the Kaplan Meier curves that depict the unadjusted
association across the antipsychotic classes with respect to
nursing home admission in the elderly beneficiaries. The
Kaplan Meier curve suggests that there was no difference
in risk of nursing home admission across typical and aty-
pical use among the beneficiaries (p = 0.88).
Table 2 presents the results of Cox proportional hazards
regression of antipsychotic use and time to nursing home
admission in the above population. Results of Cox
regression in the above cohort suggest that the average risk
of nursing home admission was similar among typical
antipsychotic users compared to atypical users (HR 0.91;
95 % confidence interval [CI] 0.81–1.01). However, due to
violation of the PH assumption, the extended Cox regres-
sion was used. The findings suggest that within the first
90 days of treatment, there was a moderately lower risk of
nursing home admission among typical users (\90 days:
HR 0.87; 95 % CI 0.77–0.97). However, the risk substan-
tially increased with prolonged typical antipsychotic
treatment [90–180 days: HR 1.58; 95 % CI 1.08–2.12].
Discussion
The current study examined the risk of nursing home
admission due to use of antipsychotics in the elderly. Both
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Table 1 Baseline characteristics of typical and atypical antipsychotic users among elderly dual-eligible beneficiaries
Characteristics Atypical antipsychotic
users in unmatched
cohort (n = 49,200)
Typical antipsychotic
users in unmatched
cohort (n = 10,931)
p value Atypical antipsychotic
users in matched
cohort (n = 10,919)
Typical antipsychotic
users in matched
cohort (n = 10,919)
p value
Age (y) 79.37 (8.37) 79.33 (8.56) 0.69 79.35 (8.32) 79.23 (8.55) 0.35
Gender [n (%)] <.0001* 0.83
Male 14,049 (28.55) 3,732 (34.14) 3,707 (33.95) 3,722 (37.09)
Female 35,151 (71.45) 7,199 (65.86) 7,212 (66.05) 7,197 (65.91)
Race [n (%)] <.0001* 0.30
White 22.393 (45.51) 4,218 (38.59) 4,205 (38.51) 4,218 (38.63)
Black 4,823 (9.8) 1,416 (12.95) 1,486 (13.61) 1,410 (12.91)
Others 21,984 (44.68) 5,297 (48.46) 5,228 (47.88) 5,291 (48.46)
Region <.0001* 0.98
New York 13,799 (28.05) 2,336 (21.37) 2,321 (21.26) 2,334 (21.38)
Florida 9,722 (19.76) 1,459 (13.35) 1,445 (13.23) 1,459 (13.36)
California 18,792 (38.20) 5,469 (50.03) 5,475 (50.14) 5,461 (50.01)




2001 38,107 (77.45) 9,382 (85.83) 9,357 (85.69) 9,370 (85.81)
2002 10,451 (21.24) 1,454 (13.30) 1,453 (13.31) 1,454 (13.32)
2003 642 (1.30) 95 (0.87) 109 (1.00) 95 (0.87)
Hospitalization in past 6 months [n (%)]
Yes 13,262 (23.96) 2,670 (24.43) <.0001* 2,717 (24.88) 2,661 (24.39) 0.38
Nursing home admission in past 6 months [n (%)]
Yes 6,819 (13.86) 971 (8.88) <.0001* 991 (9.08) 970 (8.88) 0.62
Medical history in past 6 months [n (%)]
Hypertension 5,954 (12.10) 1,117 (10.22) <.0001* 1,156 (10.59) 1,114 (10.20) 0.35
CHD 2,807 (5.71) 509 (4.66) <.0001* 548 (5.02) 508 (4.65) 0.21
CHF 3,016 (6.13) 611 (5.59) 0.03* 616 (5.64) 610 (5.59) 0.86
AMI 562 (1.14) 125 (1.14) 0.99 131 (1.20) 124 (1.14) 0.66
Dysrhythmia 2,259 (4.59) 447 (4.09) 0.02* 432 (3.96) 446 (4.08) 0.63
Circulatory
disorder
1,099 (2.23) 210 (1.92) 0.04* 204 (1.87) 209 (1.91) 0.80
Thromboembolic
disorder
288 (0.59) 53 (0.48) 0.21 46 (0.42) 53 (0.49) 0.48
Diabetes 3,208 (6.52) 657 (6.01) 0.04* 674 (6.17) 656 (6.01) 0.61
Cerebral 1,990 (4.04) 380 (3.48) 0.006* 372 (3.41) 380 (3.48) 0.77
Fracture 629 (1.28) 80 (0.73) <.0001* 85 (0.78) 80 (0.73) 0.69
COPD 2,608 (5.30) 489 (4.47) 0.0004* 495 (4.53) 487 (4.46) 0.79
Falls 80 (0.16) 8 (0.07) 0.03* 11 (0.10) 8 (0.07) 0.49
Thyroid 5,023 (10.21) 1,011 (9.25) 0.003* 1,012 (9.27) 1,011 (9.26) 0.98
Renal failure 782 (1.59) 181 (1.66) 0.62 173 (1.58) 181 (1.66) 0.66
Renal disease 2,889 (5.87) 553 (5.06) 0.0009* 539 (4.94) 552 (5.06) 0.68
Liver disease 429 (0.87) 93 (0.85) 0.83 86 (0.79) 93 (0.85) 0.59
Gastric 2,898 (5.89) 621 (5.68) 0.39 614 (5.62) 617 (5.65) 0.93
Ulcer 860 (1.75) 162 (1.48) 0.05 159 (1.46) 162 (1.48) 0.87
Cancer 1,022 (2.08) 336 (3.07) <.0001* 359 (3.29) 326 (2.99) 0.20
Cataract 35 (0.07) 4 (0.04) 0.27 4 (0.04) 4 (0.04) 1.00
Glaucoma 123 (0.25) 26 (0.24) 0.82 25 (0.23) 26 (0.24) 0.89
Anemia 1,690 (3.43) 323 (2.95) 0.01* 324 (2.97) 322 (2.95) 0.94
Osteoporosis 427 (0.87) 49 (0.45) <.0001* 55 (0.50) 49 (0.45) 0.56




cohort (n = 49,200)
Typical antipsychotic
users in unmatched
cohort (n = 10,931)
p value Atypical antipsychotic
users in matched
cohort (n = 10,919)
Typical antipsychotic
users in matched
cohort (n = 10,919)
p value
RA 113 (0.23) 17 (0.16) 0.13 18 (0.16) 17 (0.16) 0.87
Back pain 379 (0.77) 55 (0.50) 0.003* 61 (56) 55 (0.50) 0.58
Dyslipidemia 683 (1.39) 100 (0.91) <.0001* 97 (0.89) 100 (0.92) 0.83
Obesity 139 (0.28) 21 (0.19) 0.09 25 (0.23) 21 (0.19) 0.56
HIV 29 (0.06) 10 (0.09) 0.23 11 (0.10) 9 (0.08) 0.66
Pneumonia 1,608 (3.27) 333 (3.05) 0.24 311 (2.85) 333 (3.05) 0.38
Parkinson’s
disease
433 (0.88) 43 (0.39) <.0001* 53 (0.49) 43 (0.39) 0.31
Endocarditis 394 (0.80) 67 (0.61) 0.04* 71 (0.65) 67 (0.61) 0.73
Suicide 3 (0.01) 0 (0) 0.41 0 (0) 0 (0) –
Alcoholism 444 (0.90) 62 (0.57) 0.0005* 53 (0.49) 62 (0.57) 0.40
EPS 46 (0.09) 11 (0.10) 0.83 9 (0.08) 11 (0.10) 0.66
Psychiatric
disorders [n (%)]
Anxiety 434 (0.88) 50 (0.46) <.0001* 54 (0.49) 50 (0.46) 0.69
Conduct disorder 13 (0.03) 2 (0.02) 0.63 5 (0.05) 2 (0.02) 0.26
Dementia 2,780 (5.65) 392 (3.59) <.0001* 393 (3.60) 392 (3.59) 0.97
Mood disorder 1,678 (3.41) 138 (1.26) <.0001* 176 (1.61) 138 (1.26) 0.03*
Schizophrenia 955 (1.94) 100 (0.91) <.0001* 114 (1.04) 100 (0.92) 0.34
Other psychiatric
disorders
409 (0.83) 67 (0.61) 0.02* 77 (0.71) 67 (0.61) 0.40
Medication history in past 6 months
Cardiovascular 32,093 (65.23) 6,990 (63.95) 0.01* 6,966 (63.80) 6,984 (63.96) 0.79
Antidiabetic 10,263 (20.86) 2,373 (21.71) 0.04* 2,349 (21.51) 2,372 (21.72) 0.71
Analgesics 26,169 (53.19) 5,790 (52.97) 0.68 5,831 (53.40) 5,782 (52.95) 0.51
Estrogen 3,364 (6.84) 584 (5.34) <.0001* 580 (5.31) 584 (5.35) 0.90
Antihistamine 8,641 (17.56) 2,227 (20.37) <.0001* 2,282 (20.90) 2,222 (20.35) 0.32
Gastrointestinal 22,879 (46.50) 4,945 (45.24) 0.02* 4,902 (44.89) 4,934 (45.19) 0.66
Anticoagulant 11,010 (22.38) 2,195 (20.08) <.0001* 2,242 (20.53) 2,193 (20.08) 0.41
Corticosteroids 5,058 (10.28) 1,184 (10.83) 0.09 1,182 (10.83) 1,180 (10.81) 0.97
Bronchodilators 6,272 (12.75) 1,483 (13.57) 0.02* 1,482 (13.57) 1,480 (13.55) 0.97
Anti-infective 23,243 (47.24) 5,272 (48.23) 0.06 5,305 (48.59) 5,262 (48.19) 0.56
Diuretics 12,815 (26.05) 2,879 (26.34) 0.53 2,888 (26.45) 2,876 (26.34) 0.85
Anticancer 2,491 (5.06) 688 (6.29) <.0001* 722 (6.61) 677 (6.20) 0.21
Anticholinergic 3,450 (7.01) 841 (7.69) 0.01* 832 (7.62) 838 (7.67) 0.88
Alcohol drug 10 (0.02) 4 (0.04) 0.31 3 (0.03) 4 (0.04) 0.71
Ophthalmic 11,678 (23.74) 2,509 0.08 2,524 (23.12) 2,507 (22.96) 0.78
Thyroid 5,023 (10.21) 1,011 (9.25) 0.0025* 1,012 (9.27) 1,011 (9.26) 0.98
Antismoking 101 (0.21) 17 (0.16) 0.29 18 (0.16) 17 (0.16) 0.86
Endocrine 112 (0.23) 29 (0.27) 0.46 23 (0.21) 28 (0.26) 0.48
Hypnotics 9,473 (19.25) 1,664 (15.22) <.0001* 1,644 (15.06) 1,662 (15.22) 0.73
Antidepressant 18,368 (37.33) 2,643 (24.18) <.0001* 2,660 (24.36) 2,643 (24.21) 0.79
Anticonvulsant 6,821 (13.86) 1,087 (9.94) <.0001* 1,086 (9.95) 1,086 (9.95) 1.00
Lithium 260 (0.53) 24 (0.22) <.0001* 28 (0.26) 24 (0.22) 0.58
Anti-anxiety 10,958 (22.27) 2,061 (18.85) <.0001* 2,029 (18.58) 2,059 (18.86) 0.60
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typical and atypical antipsychotic agents are associated
with adverse effects in the elderly. The differential safety
profiles of typical and atypical antipsychotic agents can
have healthcare consequences such as nursing home
admission. This study found that, after controlling for
potential confounders, typical antipsychotic use was
associated with a time-dependent increase in risk of nurs-
ing home admission compared to atypical use. In the initial
phase of treatment, typical antipsychotics have a slightly
lower risk of nursing home admission (13 %); however,
with prolonged use of typical agents, the risk of nursing
home admission increases to 58 %.
The study by Lopez et al. [20] found that there is no
difference in nursing home admission among users of
typical and atypical antipsychotics in patients with prob-
able Alzheimer’s disease. However, the study did not
compare the two classes directly, and focused on long-
term nursing home admission among probable Alzhei-
mer’s patients. The study by Zuckerman et al. [19]
examined the 1-year risk of nursing home admission
among users of the inappropriate versus other antipsy-
chotics, and found a 70 % higher risk with use of other
antipsychotics. This study evaluated the risk of nursing
home admission during 6 months of antipsychotic use and
found that typical users had a time-dependent increase in
nursing home admission. However, the current study may
not be directly comparable with previous studies owing to
differences in exposure definition, outcomes measurement,
and study sample.
The study by Lopez et al. [20] further revealed that, after
controlling for underlying patient conditions like psychosis
and agitation, the risk of nursing home admission was no
longer significant for either class of antipsychotics. Zuck-
erman et al. [19] also suggested the possibility of an
indication bias to explain the high risk associated with
use of other antipsychotics compared to inappropriate
antipsychotics. The current study controlled for psychiatric
co-morbidities like anxiety, dementia, mood disorders, and
schizophrenia, which necessitate the use of antipsychotic
medications in the study population, and found that typical
Fig. 1 Distribution of







cohort (n = 49,200)
Typical antipsychotic
users in unmatched
cohort (n = 10,931)
p value Atypical antipsychotic
users in matched
cohort (n = 10,919)
Typical antipsychotic
users in matched
cohort (n = 10,919)
p value
Stimulants 143 (0.29) 16 (0.15) 0.008* 11 (0.10) 16 (0.15) 0.34
CHD coronary heart disease, CHF chronic heart failure, AMI acute myocardial infarction, COPD chronic obstructive pulmonary disease, RA
rheumatoid arthritis, HIV human immunodeficiency virus, EPS extrapyramidal syndrome
* p value significant at \0.05
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antipsychotic use had a differential risk of nursing home
admission.
Several pharmacologic mechanisms can explain the
higher risk of nursing home admission observed with
prolonged exposure to typical antipsychotics
(90–180 days). Long-term use of typical antipsychotics
could lead to extrapyramidal syndrome. The relatively
higher dopaminergic activity of typical antipsychotics
Fig. 2 Distribution of




Log-rank P-value : 0.8782
Fig. 3 Kaplan-Meier plot of crude association between users of typical and atypical antipsychotics and risk of nursing home admission
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compared to atypical agents has also been associated with
elevated prolactin levels, which in turn decreases the bone
mineral density, and may lead to falls/fractures [37, 38].
Together, these adverse events could lead to nursing home
admission among typical users. The moderately lower risk
(13 %) during the initial period of typical use (0–90 days)
may possibly be due to variable induction/latency periods
or serotonergic/histaminergic receptor blockade [39]. The
current study did not examine the specific reasons for
nursing home admission in the study population. Future
studies are therefore needed to better understand the con-
sequences of antipsychotic treatment in elderly. However,
given the high risk of nursing home admission with pro-
longed typical use (90–180 days) and safety concerns with
atypical agents, there is a need to be cautious while pre-
scribing antipsychotics in the elderly. Consequently, clin-
icians should consider prescribing the lowest dose of
antipsychotics for the shortest duration, whenever possible,
and avoid concomitant prescription of other psychotropic
medications that could predispose the residents to addi-
tional risk.
This study had several strengths. The propensity-mat-
ched retrospective cohort design involved a large number
of dual-eligible elderly users of antipsychotics. The model
included several potential confounders that could be
related to antipsychotic treatment and risk of nursing
home admission. Only new users of antipsychotics were
included in the study cohort to minimize prevalence bias
[28]. Additionally, the study focused on the dual-eligible
population, which represents one of the most understudied
populations and which has very high unmet long-term
care needs [24].
Several study limitations should be acknowledged.
Since computer-recorded information was used to capture
data, we could not ascertain whether the subjects actually
used their dispensed medicines. The diseases and outcome
measurements were based on diagnostic data in medical
claims. Incomplete records submitted by providers together
with inaccurate demographic information and clinical
details in the ICD-9-CM system may further limit the
accuracy of administrative data. A major limitation of the
current study was lack of outpatient data among the com-
munity-dwelling beneficiaries. The current study only used
inpatient data to capture the patients’ baseline character-
istics; this may have provided a limited picture of the
patients’ underlying illnesses since many patients are not
hospitalized. Additionally, variables included in the
propensity score calculation were limited to those available
in the data source; there is thus a possibility that unmea-
sured confounders such as tobacco use, nutrition, health
status, cognitive and functional limitations, and behavioral
variables might have affected the study findings [40]. Also,
results obtained from propensity score matching can only
be applicable to the final matched cohort of the population
studied due to incomplete matching. Although nursing
home admission addresses the healthcare impact of drug
utilization, it is only a generic measure, and a social con-
struct; future studies are needed to evaluate the specific
reason for nursing home admission among typical versus
atypical users. Additionally, the study focused on the vul-
nerable dual-eligible beneficiaries; the findings may not be
extrapolated to other populations or settings.
Conclusions
Antipsychotic-induced adverse events constitute a sig-
nificant public health concern owing to its associated
morbidity and mortality in the elderly. The current
propensity score-matched retrospective cohort study found
that use of typical antipsychotics was associated with a
time-dependent risk of nursing home admission. The risk
however increased with prolonged typical antipsychotic
treatment. The above study findings suggest that multiple
pharmacologic mechanisms might play an important role in
adverse events, which could lead to nursing home admis-
sion. The study reinforces the need to evaluate the con-
tributory factors of nursing home placement with
antipsychotic use among the elderly. Given the extensive
use of antipsychotic agents in the elderly, future studies
involving the short-term and long-term risk-benefit profiles
are needed to evaluate the role of antipsychotics in geriatric
pharmacotherapy.
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Table 2 Cox proportional hazard model for risk of nursing home
admission in typical antipsychotic users versus atypical antipsychotic
users among community-dwelling elderlya
Variables Hazard ratio 95 % CI p value
Multivariable analysis for antipsychotic treatment
Atypical 1.00 Reference
Typical 0.91 0.81–1.01 0.08
Multivariable analysis by time periods
\90 days of therapy 0.87 0.77–0.97 <0.01*
90–180 days of therapy 1.58 1.08–2.12 <0.02*
a Atypical antipsychotics formed reference category
* Significant at p \ 0.05
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